MedShape Receives $2.6M DOD Development Grant for Novel NiTiNOL Dynamic Compression Devices


ATLANTA, Aug. 18, 2020 /PRNewswire/ -- MedShape Inc., the industry leader in innovative NiTiNOL and other advanced material technologies, today announced that it has received a Technology/Therapeutic Development Award funded by the Department of Defense Peer Reviewed Medical Research Program (PRMRP) to assist in the research and development of a dynamic compression fusion device using superelastic nickel titanium (NiTiNOL) for use in diabetic foot limb salvage surgery. The funding award from PRMRP includes $2.6M to complete the research milestones over the next 3 years.

Nearly 5 million military Veterans suffer from diabetes mellitus with 15,000 of those also diagnosed with Charcot Foot,1,2 a painless, progressive, disease that results in the breakdown of the bones in the midfoot. Diabetic patients reportedly are 10-20 times more at risk of needing an amputation compared to non-diabetics4. In addition, those who undergo an amputation are 3 times more likely to die within 1 year of surgery compared with patients who are successfully treated through other surgical options. Given the high mortality rate, orthopaedic surgeons strive to salvage the limb with alternative surgical treatments. Currently, intramedullary (IM) screws are placed across the midfoot in an attempt to stabilize and realign the foot. However, these "beaming" devices undergo repetitive and significant loading, with 25-60% of the current devices experiencing failure, often due to loss of compressive force, implant loosening and axial migration.3,4

Through the support of the DOD research grant, MedShape, in collaboration with limb salvage specialists Dan Latt, MD/PhD (University of Arizona) and Naohiro Shibuya, DPM (Texas A&M College of Medicine), will explore the development of novel devices that maintain dynamic compression and effectively stabilize the foot in an effort to preserve the limb in the diabetic Charcot Veteran population. By leveraging MedShape's patented NiTiNOL platform technology, devices can be designed to adapt and respond to specific changes in the biological environment that occur during healing while also effectively load-sharing with the bone to reduce stress risers on the device that lead to device failure and additional surgery.

"Standard midfoot fusion devices should be robust enough to withstand weight-bearing and also able to apply compression for bone-on-bone healing. However, standard devices don't work well for diabetic patients with Charcot neuroarthropathy because their midfoot bones have deteriorated, which puts them at risk for amputation. Surgeons need a better solution, and we believe that our dynamic compression technology can be developed to address this dire need", said David Safranski, PhD, Director of Basic Research at MedShape, Inc. "Due to MedShape's extensive experience in smart (NiTiNOL-based) orthopaedic devices, we are uniquely qualified to address this clinical challenge with our Veterans. The PRMRP's support is critical for our team to develop these next-generation medical devices."

The clinical use of MedShape's internal NiTiNOL technology has already been successfully demonstrated through the company's DynaNailÒ TTC Fusion System. Ten peer-reviewed publications on the DynaNail report significantly improved clinical outcomes when treating high-risk patient populations such as diabetics and those with Charcot neuroarthropathy,5-7 suggesting the utility of the technology in other challenging fusion applications. Last month, MedShape received a small business innovation research grant to develop novel MTP replacement implants, thus reinforcing MedShape's continued commitment to advancing biomaterials research to develop state-of-the-art medical solutions.

For more information on MedShape, visit

About the DOD PRMRP Program:

The PRMRP has supported research across the full range of science and medicine, with an underlying goal of enhancing the health, care, and well-being of military Service members, Veterans, retirees, and their family members. Program oversight is provided by a programmatic panel with joint military service and interagency representation. Congressional appropriations have supported over 1600 awards in over 155 different topic areas. Congress appropriated $350 million for the FY19 program to solicit proposals in 49 topic areas.

The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Medical Research Program under Award No. W81XWH-20-1-0677. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigators adhere to the laws of the United States and regulations of the Department of Agriculture.

About MedShape, Inc.:

MedShape, Inc. is a privately held medical device company developing and commercializing medical devices that use patented, advanced material technologies to address the demand for improved joint fusion and fracture fixation in foot and ankle surgeries. For more information, visit

DynaNail is a registered trademark of MedShape, Inc.

1Franklin H, Rajan M, Tseng CL, Pogach L, Sinha A, Mph M. Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010. Journal of rehabilitation research and development 2014; 51(8): 1325-30.

2Ahn P. Veteran Population Projection Model 2016 Executive Summary. In: Affairs DoV, editor.; 2017.

3.Eschler A, Wussow A, Ulmar B, Mittlmeier T, Gradl G. Intramedullary medial column support with the Midfoot Fusion Bolt (MFB) is not sufficient for osseous healing of arthrodesis in neuroosteoarthropathic feet. Injury 2014; 45 Suppl 1: S38-43.

4Butt DA, Hester T, Bilal A, Edmonds M, Kavarthapu V. The medial column Synthes Midfoot Fusion Bolt is associated with unacceptable rates of failure in corrective fusion for Charcot deformity. Bone & Joint Journal 2015; 97-B(6): 809.

5Dupont KM, Shibuya N, Bariteau JT. Tibiotalocalcaneal Arthrodesis with Intramedullary Nails – Mechanobiological Background and Evolution of Compressive Technology. Global J of Orthopedics Research, 2019. 1(5): 1-8.

6Steele JR, Easley ME, Nunley JA, Adams SB, et al. Comparison of Tibiotalocalcaneal Arthrodeses Using a Sustained Dynamic Compression Nail Versus Nondynamized Nails. Foot & Ankle Spec, 2020. 13(3): 193-200.

7Ford SE, Kwon JY, Ellington K. Tibiotalocalcaneal Arthrodesis Utilizing a Titanium Intramedullary Nail With an Internal Pseudoelastic Nitinol Compression Element: A Retrospective Case Series of 33 Patients. J Foot Ankle Surg, 2019. 58(2): 266-272.

Media Contact:
Jenn Pratt
Carabiner Communications

Company Contact:
Kathryn Smith, Ph.D.

Cision View original content:

SOURCE MedShape, Inc.


Back to news